Syndi is a digital health platform that focuses on enhancing health outcomes through technology and research, initially targeting mental health. The platform employs machine learning and digital phenotyping to provide personalized and immediate care by utilizing moment-by-moment passive smartphone data collection. This approach allows for effective and accessible support tailored to individual needs. Syndi's services aim to improve the treatment of invisible disabilities by facilitating connections between patients and healthcare providers, while also measuring the effectiveness of its applications and digital services. Through its innovative solutions, Syndi seeks to transform the way people access and engage with healthcare.
52 North Health is focused on enhancing healthcare for cancer patients, specifically those undergoing chemotherapy, by providing a portable and easy-to-use medical device. This device employs artificial intelligence to assess the risk of neutropenic sepsis, a serious and potentially fatal side effect of chemotherapy. Through a finger prick blood test and a corresponding digital platform, the device measures a patient's neutrophil count and C-reactive protein (CRP) levels at home. This functionality allows for timely identification of patients at risk of sepsis, thereby improving their safety and quality of life. By facilitating rapid management of their condition, 52 North Health offers a reliable and cost-effective solution for cancer patients.
PhysioMedics is a healthcare technology company which provides online software solutions to reduce costs and improve efficiencies in managing musculoskeletal disorders.
Sequential Skin is a diagnostic platform company targeting skin longevity and aging. Our team specialises in genetics, epigenetics, and the skin microbiome.
CONNECT Care gives patients the confidence to manage their medications.
Kynos Therapeutics develops KMO inhibitors across key indications in inflammation, immunity, and metabolism.
Medwise.ai is an AI-powered, community-curated platform to answer all of your day to day clinical questions.
CONNECT Care gives patients the confidence to manage their medications.
Oxford Heartbeat develop medical device software that makes planning for surgeries simpler, faster and more accurate. It enables surgeons to unlock and visualise crucial information in preparation for surgery, to see what is happening inside blood vessels, travel through tissues and bones and provides unprecedented visibility for keyhole surgeries. With the combined power of predictive computations, big data and AI, they provide a unique solution for rehearsing procedures and choosing the best surgical scenario for each individual patient in advance. Better preparation means reduced complication rates and associated costs, as well as better patient care.
AgPlus Diagnostics Ltd. is a company specializing in the development of a diagnostic platform technology aimed at providing quantitative point-of-care products for various clinical applications, including human and veterinary diagnostics. Established in 2009 and headquartered in Sharnbrook, United Kingdom, the company designs, manufactures, and supplies diagnostic tests and accompanying readers. AgPlus Diagnostics employs an electrochemical reader and measurement system that enables personalized healthcare by delivering rapid diagnostic results based on individual biomarker profiles. This technology allows healthcare providers to make critical treatment decisions in a matter of minutes, enhancing the efficiency of patient care.
Developer of fertility therapy devices designed to provide clinical-standard treatment at home. The company's product contains ovulation assessments, insemination units, pregnant assessments, semen pattern assortment pots, and entry to an application to assist in observing ovulation dates, enabling customers to access affordable fertility treatment in the comfort of their houses.
Camallergy Limited, founded in 2015 and based in Cambridge, United Kingdom, specializes in the development and manufacture of oral immunotherapy drugs targeting food allergies, particularly peanut allergies. The company's innovative treatments aim to provide a patient-centric solution that offers rapid protection, allowing individuals to manage their allergies effectively within a few weeks of therapy. By focusing on the needs of those affected by food allergies, Camallergy seeks to enhance the quality of life for patients, enabling them to live without the constant fear associated with allergic reactions.
4D Medicine specializes in creating innovative solutions for the targeted and controlled regeneration of human tissue through the development of degradable, implantable medical devices. Utilizing novel photopolymer materials, the company is advancing a range of products that are currently undergoing regulatory clearance with the Food and Drug Administration. These resorbable medical devices aim to enhance patient outcomes in various applications, including musculoskeletal surgery, soft tissue repair, and drug delivery. By focusing on regulatory approval and effective medical applications, 4D Medicine seeks to provide valuable options for medical device suppliers and healthcare providers.
Oxford Endovascular are developing a novel treatment for treating brain aneurysms. The Oxford technology uses a special laser-cut metal alloy which has a shape-memory. It can be posted into a catheter during surgery, inserted into the brain and opened up into a tiny tube mesh (‘flow diverter’) that fits into the natural shape of the blood vessel. This diverts the blood away from the aneurysm, allowing it to heal.
Ingenion Medical is a medical device company focused on developing innovative solutions for patients suffering from chronic urinary retention and incontinence. The company's products aim to mimic natural urination, thereby eliminating the need for drainage bags. By prioritizing clinically relevant and cost-effective designs, Ingenion Medical addresses critical issues related to urinary flow and control, enhancing the quality of life for its users.
BioFab is developing innovative new products for healthcare diagnostics with a particular focus on point-of-care testing (POCT) applications. Our vision is to create a truly universal diagnostic platform that can bring the clinical lab to the patient. Our innovative approach will enable this vision by offering a diverse range of test cartridges which can run on a single, universal reader device. It will not need any user training and will simply require the addition of the patient sample. Fully automated processing will then take place in a totally enclosed cartridge and will then deliver laboratory grade results without risk of cross-contamination. We are developing a test for Covid-19 with the support of an Innovate UK Smart award and will expand the product range to cover cardio-vascular disease, respiratory/gastric infections, blood infections (sepsis), STDs, Cancer and other conditions. We also have the ability to access the rapidly expanding Chinese market and have route-to-market and manufacturing base via established partners in China.
AgPlus Diagnostics Ltd. is a company specializing in the development of a diagnostic platform technology aimed at providing quantitative point-of-care products for various clinical applications, including human and veterinary diagnostics. Established in 2009 and headquartered in Sharnbrook, United Kingdom, the company designs, manufactures, and supplies diagnostic tests and accompanying readers. AgPlus Diagnostics employs an electrochemical reader and measurement system that enables personalized healthcare by delivering rapid diagnostic results based on individual biomarker profiles. This technology allows healthcare providers to make critical treatment decisions in a matter of minutes, enhancing the efficiency of patient care.
Cognitant helps people to better understand their health. We create immersive content, and connect patients to relevant information endorsed by doctors. Our aim is to help doctors and patients make the most of their valuable consultation time.
Directed Systems develops and markets clinical decision support and control systems specifically tailored for anaesthesia, intensive care, and burns centres. The company focuses on creating medical software that facilitates data-driven clinical decisions through clinical optimization applications designed for time-critical conditions. These applications operate using real-time patient monitoring data and include FDA-cleared solutions for cardiovascular management in operating rooms. Directed Systems is also expanding its platform to cover recovery and intensive care settings. By accumulating a vast dataset, the company leverages analytics and AI tools to enhance performance, enabling healthcare professionals to make informed decisions that improve patient outcomes and minimize complications.
Closed Loop Medicine Ltd is a healthcare technology company based in Cambridge, United Kingdom, founded in 2017. The company focuses on developing innovative therapeutic solutions that combine established medications with proprietary digital therapeutics. By digitizing and capturing data throughout the entire care continuum, Closed Loop Medicine seeks to create dynamic, personalized treatment regimens tailored to individual patient needs. Their pipeline includes integrated approaches that address significant health challenges such as sleep disorders, hypertension, chronic pain, and diabetes. Through real-time feedback and advanced care pathways, Closed Loop Medicine aims to enhance patient outcomes and improve the overall efficiency of healthcare delivery.
Ampersand is pioneering the development of behavioural science based digital medicines for people living with long term inflammatory conditions. We deliver measurable improvements in mental health and quality of life for patients and significant, well-evidenced savings for healthcare providers.
Albus Health is a medical device company that develops a passive and non-contact, nocturnal symptom monitoring device. The company develops Albus Home RD, a completely passive and non-contact home monitoring device that enables a high quantity and quality of data from remote monitoring in research and clinical care.
Developer of home-monitoring applications designed to measure eyesight. The company's software combines vision science and computer science to measure sight as precisely and reliably as physically possible, enabling patients who are at high risk of eye disease to self-monitor from home and avoid the hospital. .
Medwise.ai is an AI-powered, community-curated platform to answer all of your day to day clinical questions.
In modern healthcare, not only must we focus on prolonging a person's life, but also on maintaining the quality of that life. Functional health information is a powerful tool enabling clinicians to maintain patient quality of life, but it is let down by imperfect assessment tools that are subjective, have poor repeatability and are insensitive to incremental change. Vitrue is a huge leap in functional assessment accuracy and efficiency. Our system will enable occupational and physical therapists to treat more patients, more effectively by providing them with far more advanced and modern assessment tools.
Arete Medical Technologies is a startup creating medical devices and software for precision approaches to chronic diseases, starting with asthma and COPD.
Xploro is a health information platform aimed at young patients, utilizing augmented reality, gameplay, and artificial intelligence to deliver health-related content. This innovative mobile application empowers children by providing them with engaging and informative resources, helping to alleviate stress and anxiety associated with medical procedures. By combining entertainment with education, Xploro enhances patient understanding and involvement in their health care, ultimately aiming to improve clinical outcomes for young users. The platform is clinically validated and has received recognition for its effectiveness in transforming the way health information is communicated to children.
Kheiron Medical Technologies Limited develops Mia, a mammography intelligent assessment tool that helps radiologists to detect breast cancer. Kheiron Medical Technologies Limited was formerly known as Maesterai Limited and changed its name to Kheiron Medical Technologies Limited in June 2016. The company was incorporated in 2016 and is based in London, United Kingdom with an additional location in San Francisco, California.
Arete Medical Technologies is a startup creating medical devices and software for precision approaches to chronic diseases, starting with asthma and COPD.
Marion Surgical Inc. specializes in developing and manufacturing virtual reality surgical simulator solutions aimed at enhancing surgical training. The company offers products such as the K181 PCNL and Kidney Access Array, designed for training in percutaneous access procedures under real-time fluoroscopy, and the PTE Simulator, which focuses on pulmonary thrombo-endarterectomy surgery. These simulators provide a realistic and safe training environment, allowing surgeons to learn, collaborate, and practice procedures effectively. Founded in 2016, Marion Surgical is headquartered in Niagara Falls, Canada, with an additional office in Salford, United Kingdom. The company emphasizes customizable training experiences to meet the specific needs of various surgical procedures and patient scenarios.
The Sixth Sense in medical Diagnostics. At AINOSTICS we are working to identify the earliest biological signs of some of our society’s most devastating neurodegenerative conditions such as Alzheimer’s disease, Huntington's and MS, providing the best chance of success in the development of potential preventions and therapeutics by Pharma, and precise treatment planning by clinicians. We combine the most exciting medical imaging innovations with the best of artificial intelligence solutions to unlock the future of personalised diagnosis, prognosis, and therapy monitoring and planning.
ExplantLab is an independent research organization located in Newcastle upon Tyne, United Kingdom. The company focuses on exploring the connections between patient genetics and the design, manufacture, and performance of medical devices. By integrating genetic insights into its research, ExplantLab aims to enhance the effectiveness and safety of medical devices, ultimately improving the quality of life for patients.
Appt is making preventive healthcare effortless and accessible. Appt uses behavioural economics and data analytics to increase the uptake of preventive healthcare appointments - earning practices additional income and helping the delivery of nationally set prevention targets. Furthermore, through end-to-end automation of the call and recall process, Appt reduces cumbersome practice workload saving practice staff valuable time.
Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, specializing in tissue regenerative implants for patients with knee injuries. Founded in 2008 by Dr. Nick Skaer and Professor Oliver Kessler, the company leverages silk technology developed at Oxford University to create innovative solutions for cartilage and meniscus repair. Its primary products include FibroFix, a biomaterial designed to replicate human knee cartilage; FibroFix Meniscus, which focuses on repairing and regenerating meniscal cartilage; and FibroFix Cartilage, aimed at treating articular cartilage damage. The technology behind these products was originally developed at Oxford Biomaterials Ltd., where Dr. Skaer played a significant role in advancing the FibroFix technology platform before securing exclusive licenses for its application in cartilage and bone repair.
Cyted focuses on providing digital diagnostic infrastructure to drive the earlier detection of disease. Our technologies use artificial intelligence and novel biomarkers to unlock clinical insight and improve patient outcomes. Cyted's mission is to revolutionise diagnostic methods to build a world where disease is prevented rather than treated.
Sense Biodetection Limited is a molecular diagnostics company based in Abingdon, United Kingdom, established in 2013. The company specializes in developing innovative, user-centered, handheld diagnostic tests aimed at enhancing healthcare decisions, particularly in the fields of infections and oncology. Its flagship product, True Point-of-Care, serves as a clinical diagnostic tool that empowers users to make informed treatment decisions in a decentralized healthcare environment. By employing advanced molecular methods, including polymerase chain reaction (PCR) technology, Sense Biodetection's equipment allows clinics and medical professionals to detect infections promptly and effectively, facilitating immediate treatment options.
Echopoint Medical Ltd is a medical device company based in London, United Kingdom, focused on developing optical-fibre based sensors for use in minimally invasive procedures, particularly in the field of cardiology. Founded in 2018 as a spin-out from University College London, the company aims to enhance precision in the diagnosis and treatment of cardiovascular diseases. By leveraging advancements in fibre optic sensor technology, Echopoint Medical seeks to address significant unmet needs within healthcare, providing devices that offer exceptional sensing and imaging capabilities. These innovations are designed to improve patient outcomes while reducing costs and complications associated with cardiac surgeries.
Px HealthCare (Px) has developed the only validated, personalised medical support platform for cancer patients, called OWise, which has been demonstrated to improve the patient – physician relationship and is designed to improve users quality of life and even survival. Originally developed in the Netherlands, the award-winning mobile app ‘OWise breast cancer’ has been independently studied, revealing that 90% of the patients and 90% of the treating clinicians recommend OWise to breast cancer patients. With the widespread use of smartphones, OWise is designed to support patients as part of their everyday life during treatment. NHS England has selected OWise to be part of its Innovation Accelerator (2015) and it was listed in the Top25 of all health apps (by IQVIA, 2017). The focus is currently on breast cancer as so many women are affected by the condition and the impact, both mentally and physically, is big. Through the website (www.owise.nl / www.owise.eu) and the OWise smartphone app, Px HealthCare offers women (and men) smart internet tools which helps them gaining insight into and control over their situation during and after illness. Px HealthCare is a life sciences company, founded in 2012.
Closed Loop Medicine Ltd is a healthcare technology company based in Cambridge, United Kingdom, founded in 2017. The company focuses on developing innovative therapeutic solutions that combine established medications with proprietary digital therapeutics. By digitizing and capturing data throughout the entire care continuum, Closed Loop Medicine seeks to create dynamic, personalized treatment regimens tailored to individual patient needs. Their pipeline includes integrated approaches that address significant health challenges such as sleep disorders, hypertension, chronic pain, and diabetes. Through real-time feedback and advanced care pathways, Closed Loop Medicine aims to enhance patient outcomes and improve the overall efficiency of healthcare delivery.
Ampersand is pioneering the development of behavioural science based digital medicines for people living with long term inflammatory conditions. We deliver measurable improvements in mental health and quality of life for patients and significant, well-evidenced savings for healthcare providers.
Healum is a developer of connected software and applications aimed at enhancing self-management for individuals with long-term health conditions. The company's AI-powered platform offers personalized care and support by leveraging data-driven insights and evidence-based behavioral interventions. This approach not only helps patients monitor their physical and mental health effectively but also empowers healthcare professionals to provide tailored assistance. By focusing on customized interventions, Healum seeks to motivate patients in managing their chronic health issues more efficiently and cost-effectively.
Albus Health is a medical device company that develops a passive and non-contact, nocturnal symptom monitoring device. The company develops Albus Home RD, a completely passive and non-contact home monitoring device that enables a high quantity and quality of data from remote monitoring in research and clinical care.
Feebris Ltd is a technology company founded in 2017 and based in Saffron Walden, United Kingdom. The company specializes in developing artificial intelligence and machine learning algorithms aimed at the detection of respiratory conditions. Its platform integrates with various point-of-care devices, such as digital stethoscopes and wearables, to facilitate community-based diagnosis and monitoring. By leveraging its AI-driven software, Feebris enables non-clinical users to identify clinical deterioration early, thereby helping to prevent complications and reduce hospitalizations. The team at Feebris combines expertise in biomedical engineering, machine learning, and global health, all driven by a commitment to transforming healthcare into a more equitable, personalized, and patient-centered system.
Our mission is to transform how decisions are made about our health. Decisions informed by patient outcomes, and shared by patient and clinician. Shared decisions, digital consent, better outcomes. Our digital consent platform uses data to inform and design to simplify complexity. Secure, auditable, and a great experience for all our users.
In modern healthcare, not only must we focus on prolonging a person's life, but also on maintaining the quality of that life. Functional health information is a powerful tool enabling clinicians to maintain patient quality of life, but it is let down by imperfect assessment tools that are subjective, have poor repeatability and are insensitive to incremental change. Vitrue is a huge leap in functional assessment accuracy and efficiency. Our system will enable occupational and physical therapists to treat more patients, more effectively by providing them with far more advanced and modern assessment tools.
DJS Antibodies Ltd, founded in 2014 and based in Bicester, United Kingdom, specializes in the design and discovery of innovative therapeutic monoclonal antibodies targeting G-protein-coupled receptors (GPCRs). The company is focused on addressing significant unmet medical needs through the development of new medicines, an inherently challenging process often hindered by traditional methodologies. DJS Antibodies utilizes a breakthrough technology that enhances the success rate of discovering lead antibodies, a process that has garnered early support from Johnson & Johnson. This approach has facilitated the advancement of lead programs aimed at treating cancer and kidney disease, positioning DJS Antibodies as a leader in the field of drug development.
COHESION Medical Ltd. is a Connected Citizen Health company building the safest, smartest and most streamlined health system in the world, improving global population health and wellness. COHESION.OS is making citizens more empowered, services more efficient and sciences more innovative.
It is our mission to be a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases to improve survival and quality of life. Dxcover are an award-winning team, dedicated to developing liquid biopsies for early detection of cancer and other diseases. A University of Strathclyde spinout in 2019 under the name ClinSpec Diagnostics, and rebranded as Dxcover Limited in 2021. To date, Dxcover have secured £5.1m of funding, and have successfully completed two ground-breaking clinical studies on detection of brain cancer and are currently developing our platform for the detection of commonly occurring cancers.
Mendelian is a company focused on accelerating the diagnosis of rare genetic diseases. By utilizing an intelligent agent, Mendelian analyzes patients' clinical features to identify the genes responsible for rare conditions. Physicians input phenotypic details, and the platform generates outputs that indicate potential causative genes and mutations. This innovative approach enhances the investigation of undiagnosed cases, allowing for earlier detection and treatment of rare diseases through machine learning and knowledge reasoning.
MediSieve Ltd. is a London-based medical device company that specializes in developing Magnetic Blood Filtration (MBF) technology for the treatment of blood-borne diseases. The company’s innovative device employs a magnetic filter to remove infected blood cells, making it applicable for conditions such as malaria, leukemia, and sepsis. MediSieve’s system operates by circulating a patient’s blood through an external loop, where targeted magnetic particles bind to specific disease-related targets. The blood is then filtered through a magnetic device that captures these particles and their attached targets, allowing the remainder of the blood to return to the patient without contamination. Founded in 2014 and located at the Imperial Incubator in White City, London, MediSieve has dedicated facilities for product development and validation, including capabilities for various blood testing methods.
COHESION Medical Ltd. is a Connected Citizen Health company building the safest, smartest and most streamlined health system in the world, improving global population health and wellness. COHESION.OS is making citizens more empowered, services more efficient and sciences more innovative.
BIOS Health is a company based in Cambridge, United Kingdom, that specializes in developing a neural interface platform aimed at treating chronic health conditions. Founded in 2015, BIOS integrates advances in hardware, big data, and machine learning to create solutions that decode and encode neural signals from the body. The company also focuses on the development of prosthetic connectors, which standardize the connection between bionic devices and the body’s neural and soft-tissue systems. These implanted medical devices are designed to link nerve activity to specific conditions, facilitating precise communication and control for patients using prosthetics. BIOS operates an additional research and development office in Montreal, Canada.
Medherant Limited is a clinical-stage company based in Coventry, United Kingdom, focused on developing innovative treatments for pain and central nervous system diseases through advanced transdermal drug delivery technology. Founded in 2014 by Professor David Haddleton in collaboration with the University of Warwick, Medherant aims to address the limitations of existing patch technologies, which often struggle with drug loading capabilities and are unsuitable for many pharmaceutical products. The company's flagship product, the TEPI Patch, utilizes a novel adhesive that enhances drug delivery by allowing for higher concentrations and faster release rates, while mitigating the issues associated with oral medications, such as gastrointestinal toxicity and low bioavailability.
Metrion Biosciences Ltd is a contract research organization specializing in preclinical drug discovery services. Founded in 2015 and based in Cambridge, United Kingdom, the company offers a comprehensive range of services that include ion channel screening, cardiac safety profiling, and neuroscience assays. Metrion provides flexible business models tailored to the needs of its clients, which encompass both fee-for-service and collaborative options. The company is equipped with advanced electrophysiology screening capabilities to support medicinal chemistry optimization programs and integrated drug discovery efforts, ensuring high-quality and compliant preclinical testing.
Lightpoint Medical, Ltd., a medical device company, develops imaging technologies for cancer surgery. It develops Cerenkov Luminescence Imaging technology that detects cancer in real-time during surgery, and reduces the likelihood of cancer recurrence and the need for reoperation. Lightpoint Medical, Ltd. was formerly known as Artemis Diagnostics Ltd. and changed its name to Lightpoint Medical, Ltd. in January 2013. The company was founded in 2012 and is based in Rickmansworth, United Kingdom.
Oxford Heartbeat develop medical device software that makes planning for surgeries simpler, faster and more accurate. It enables surgeons to unlock and visualise crucial information in preparation for surgery, to see what is happening inside blood vessels, travel through tissues and bones and provides unprecedented visibility for keyhole surgeries. With the combined power of predictive computations, big data and AI, they provide a unique solution for rehearsing procedures and choosing the best surgical scenario for each individual patient in advance. Better preparation means reduced complication rates and associated costs, as well as better patient care.
Mayden is a company that provides managed web applications and custom system development specifically for the healthcare sector. They focus on creating innovative, flexible, and cloud-based software solutions that enhance patient management, operational management, online service assessment, and secure hosting. By designing and supporting interoperable systems and platforms, Mayden aims to help healthcare providers deliver data-driven, outcome-focused, and patient-centered care. The company is based in the areas of Bath and Chippenham and employs 44 staff members, along with a network of skilled associates who contribute to specific projects. Mayden is committed to adding real value to healthcare by developing applications that transform service delivery for healthcare professionals and improve patient experiences.
Kiroku Limited is a software company based in Harrow, United Kingdom, founded in 2017. The company specializes in developing an artificial intelligence-driven platform that automates the process of writing clinical notes for healthcare providers. By utilizing voice recognition, language processing, and AI algorithms, Kiroku's software enhances the efficiency of healthcare professionals by streamlining workflows and learning individual note-taking styles. This innovation aims to reduce the burden of documentation, allowing medical professionals to focus more on patient care while improving the quality of the information captured in clinical notes.
MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, focused on developing a novel class of anti-infective medicines derived from DNA Minor Groove Binders (MGB). Established in 2009, the company is dedicated to creating small molecule antibacterial agents effective against both multi-resistant and susceptible Gram-positive pathogens. One of its key products, MGB-BP-3, is being developed in an oral formulation for the treatment of Clostridium difficile associated disease. By targeting bacteria through a unique mode of action, MGB Biopharma aims to address the challenge of antibiotic resistance, offering healthcare providers more effective treatment options for bacterial infections. The experienced team at MGB Biopharma leverages expertise from the pharmaceutical and biotechnology sectors to drive its innovative research and development efforts.
PulmonIR is focused on the research and development of innovative medical devices aimed at detecting and monitoring lung diseases, particularly chronic obstructive pulmonary disease (COPD) and lung cancer. The company's technology is designed to assist healthcare professionals in diagnosing COPD patients more efficiently, allowing for quicker and safer treatment options for those suffering from these conditions. By streamlining the testing process, PulmonIR aims to improve patient outcomes and enhance the overall management of lung diseases.
AccuRx Limited is a London-based company established in 2016 that specializes in developing text messaging software for healthcare professionals. Its platform facilitates communication between General Practitioner (GP) practices and patients, offering features such as appointment booking, patient questionnaires, online consultations, and video consultations. The Chain messaging feature allows medical practitioners to send advice, notify patients of test results, and remind them to schedule appointments. Since its inception, AccuRx has expanded its reach significantly, now serving 20% of GP practices in England. The company aims to enhance the connection between patients and their healthcare teams, improving overall communication and patient engagement.
Metrion Biosciences Ltd is a contract research organization specializing in preclinical drug discovery services. Founded in 2015 and based in Cambridge, United Kingdom, the company offers a comprehensive range of services that include ion channel screening, cardiac safety profiling, and neuroscience assays. Metrion provides flexible business models tailored to the needs of its clients, which encompass both fee-for-service and collaborative options. The company is equipped with advanced electrophysiology screening capabilities to support medicinal chemistry optimization programs and integrated drug discovery efforts, ensuring high-quality and compliant preclinical testing.
Stratified Medicine Scotland Innovation Centre is based in the University of Glasgow’s Clinical Innovation Zone at the Queen Elizabeth University Hospital (QEUH) campus in Glasgow.SMS-IC is a unique consortium of partners, comprising NHS Scotland, four Scottish Universities(Glasgow, Edinburgh, Dundee and Aberdeen) and industrial partners across informatics and genomics (Aridhia Ltd and ThermoFisher Ltd).
Arete Medical Technologies is a startup creating medical devices and software for precision approaches to chronic diseases, starting with asthma and COPD.
MyWay Digital Health is a comprehensive online self management platform. Improving the lives of people living with long-term conditions around the globe through data-driven technology solutions.
MIOTIFY Ltd. develops software and online toolkit to boost the quality of digital health applications. The company's system allows both developers and non-IT staff to create applications within a guided framework to help them build in quality from the start and auto-generate evidence to include in a submission for regulatory approval. MIOTIFY Ltd. provides new data to enable medics to monitor patients remotely and gather insights to inform their treatment. MIOTIFY Ltd. was incorporated in 2015 and is based in Windsor, United Kingdom.
Renephra Ltd is a medical device company developing a groundbreaking Transdermal Fluid Removal (TFR) technology for minimally invasive fluid removal.
We are targeting the significant problems of fluid overload and chronic oedema / lymphoedema in vascular, oncology and other disease areas.
This is a substantial patient group with unmet clinical needs and is an estimated £1billion market worldwide.
Having achieved proof of concept in humans, Renephra is raising £400k to conduct device development study and design feasability.
DJS Antibodies Ltd, founded in 2014 and based in Bicester, United Kingdom, specializes in the design and discovery of innovative therapeutic monoclonal antibodies targeting G-protein-coupled receptors (GPCRs). The company is focused on addressing significant unmet medical needs through the development of new medicines, an inherently challenging process often hindered by traditional methodologies. DJS Antibodies utilizes a breakthrough technology that enhances the success rate of discovering lead antibodies, a process that has garnered early support from Johnson & Johnson. This approach has facilitated the advancement of lead programs aimed at treating cancer and kidney disease, positioning DJS Antibodies as a leader in the field of drug development.
MedaPhor Limited is an e-learning company based in Cardiff, United Kingdom, that specializes in creating training products for postgraduate medical professionals. The company focuses on enhancing ultrasound examination techniques through its innovative simulation technology solutions. MedaPhor's offerings include Blue Phantom, which provides ultrasound phantoms for hands-on simulation training in gynaecology and obstetrics, and True Anatomy, an endovaginal training model designed for ultrasound simulation. Additionally, MedaPhor develops models for intrauterine pregnancy, ectopic pregnancy, and general pathology, contributing to the advancement of medical education and training. Established in 2004, MedaPhor aims to improve the skills and knowledge of healthcare practitioners through its comprehensive training solutions.
Albus Health is a medical device company that develops a passive and non-contact, nocturnal symptom monitoring device. The company develops Albus Home RD, a completely passive and non-contact home monitoring device that enables a high quantity and quality of data from remote monitoring in research and clinical care.
Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, specializing in the development of diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care environments. The company's flagship products include the io System, which detects infectious diseases such as chlamydia and MRSA, and Callisto, designed to accommodate various testing throughput requirements. Binx Health focuses on providing solutions for sexually transmitted infections and hospital-acquired infections. The company aims to enhance healthcare accessibility by delivering on-demand testing directly to consumers, utilizing its proprietary, desktop, PCR-based platforms and mobile offerings. Established in 2005, Binx Health has formed a strategic partnership with Sherlock Biosciences to further advance its innovative healthcare solutions.
AgPlus Diagnostics Ltd. is a company specializing in the development of a diagnostic platform technology aimed at providing quantitative point-of-care products for various clinical applications, including human and veterinary diagnostics. Established in 2009 and headquartered in Sharnbrook, United Kingdom, the company designs, manufactures, and supplies diagnostic tests and accompanying readers. AgPlus Diagnostics employs an electrochemical reader and measurement system that enables personalized healthcare by delivering rapid diagnostic results based on individual biomarker profiles. This technology allows healthcare providers to make critical treatment decisions in a matter of minutes, enhancing the efficiency of patient care.
Entia Ltd is a medical technology company based in London, United Kingdom, that focuses on enhancing access to blood tests through innovative healthcare devices. Founded in 2014, Entia offers two primary products: Aptus, a device for testing haemoglobin and haematocrit levels, and Affinity, designed for cancer patients to monitor their blood counts from home. These devices facilitate health screening, blood donor screening, maternal and child health, nutrition, and sports applications, while also enabling cancer patients to manage their health more effectively, reducing the risk of infection and minimizing hospital visits. The company employs a multidisciplinary team that encompasses design, engineering, quality assurance, and business development, all aimed at improving patients' quality of life by allowing them to conduct essential health monitoring from the comfort of their homes.
Arquer Diagnostics Ltd. specializes in the design, development, and commercialization of non-invasive immunoassay diagnostic tests for bladder and prostate cancer. The company offers an enzyme-linked immunosorbent assay (ELISA) for measuring small amounts of substances in body fluids, including a CE-marked ELISA kit for Mcm5, which is utilized in hospital pathology laboratories. Additionally, Arquer provides a point-of-care system that features a robust reader instrument and disposable cartridges, allowing for immediate testing in urology clinics, hospital laboratories, and general practitioners' surgeries. Founded in 2005 and formerly known as UroSens Ltd., the company is headquartered in Sunderland, United Kingdom, and is committed to improving cancer detection and monitoring to enhance patient outcomes.
Current Health Limited, founded in 2014 and based in Edinburgh, United Kingdom, specializes in developing wearable healthcare devices that monitor patients' vital signs. These devices are designed to measure key health metrics such as oxygen saturation, respiration rate, pulse rate, temperature, motion, activity, and posture, allowing for the early identification of unwell patients and timely medical intervention. The company also offers a patient monitoring platform that facilitates home-based care by enabling patients to share daily activities, report symptoms, and respond to structured questionnaires for their healthcare providers. By focusing on remote patient management, Current Health aims to reduce healthcare risks and costs while enhancing patient engagement and monitoring. Formerly known as Snap40 Limited, the company rebranded in December 2018 to better reflect its mission.
Oxford Heartbeat develop medical device software that makes planning for surgeries simpler, faster and more accurate. It enables surgeons to unlock and visualise crucial information in preparation for surgery, to see what is happening inside blood vessels, travel through tissues and bones and provides unprecedented visibility for keyhole surgeries. With the combined power of predictive computations, big data and AI, they provide a unique solution for rehearsing procedures and choosing the best surgical scenario for each individual patient in advance. Better preparation means reduced complication rates and associated costs, as well as better patient care.
MIRA Rehab is a company focused on enhancing the rehabilitation experience for patients recovering from surgery or injury. It has developed a motion-tracking therapy platform that transforms traditional physical therapy exercises into engaging video games. Utilizing a motion sensor like Microsoft Kinect, the system tracks user movements from a distance, allowing for a hands-free assessment of performance and compliance. This innovative approach not only makes rehabilitation more enjoyable but also tailors the experience to meet the specific needs of different pathologies. By creating a motivating environment, MIRA Rehab aims to facilitate faster recovery and improve patient outcomes in physical therapy.
Azul Optics is developing a device that can rapidly assess macular pigment density. Their device will be affordable, fast, easy-to-use and compact, making it easy to integrate macular pigment density screening into regular eye exams.
Their goal is to introduce a technology that enables eye health professionals to rapidly assess macular pigments as an indicator of eye health.
Renephra Ltd is a medical device company developing a groundbreaking Transdermal Fluid Removal (TFR) technology for minimally invasive fluid removal.
We are targeting the significant problems of fluid overload and chronic oedema / lymphoedema in vascular, oncology and other disease areas.
This is a substantial patient group with unmet clinical needs and is an estimated £1billion market worldwide.
Having achieved proof of concept in humans, Renephra is raising £400k to conduct device development study and design feasability.
DynamX Medical specializes in the development of a cost-effective and reliable precancer screening system designed for rapid tissue biopsy analysis. This innovative technology enables point-of-care operation, allowing nurses to efficiently conduct screenings in various clinical settings. The company's focus on creating accessible diagnostic tools aims to enhance the identification of healthy and benign tissue specimens, ultimately improving patient care and outcomes. Established in London, United Kingdom, DynamX Medical has positioned itself at the forefront of advancements in medical diagnostics since its inception.
Isansys Lifecare is a new generation medical device and healthcare information company.
DJS Antibodies Ltd, founded in 2014 and based in Bicester, United Kingdom, specializes in the design and discovery of innovative therapeutic monoclonal antibodies targeting G-protein-coupled receptors (GPCRs). The company is focused on addressing significant unmet medical needs through the development of new medicines, an inherently challenging process often hindered by traditional methodologies. DJS Antibodies utilizes a breakthrough technology that enhances the success rate of discovering lead antibodies, a process that has garnered early support from Johnson & Johnson. This approach has facilitated the advancement of lead programs aimed at treating cancer and kidney disease, positioning DJS Antibodies as a leader in the field of drug development.
MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.
Sky Medical Technology Limited develops innovative neuromuscular electro-stimulation medical devices aimed at enhancing vascular health. Their flagship products include the geko device, which stimulates the common peroneal nerve to activate muscle pumps and improve blood flow, and the firefly device, designed for athletes to enhance lower limb circulation for quicker recovery. The company's OnPulse™ therapy represents a significant advancement in bioelectronic medicine, offering clinically proven solutions for various acute and chronic circulatory conditions, including the prevention of blood clots, treatment of swelling post-surgery, and management of non-healing wounds. These devices are utilized by healthcare professionals, including surgeons, nurses, physiotherapists, and podiatrists, across NHS and private hospitals, as well as in clinical studies. Sky Medical Technology distributes its products globally, reaching markets in Asia, Europe, the Middle East, and North America. Founded in 2006 and based in High Wycombe, United Kingdom, the company addresses the needs of over forty million individuals facing vascular-related health challenges.
Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, specializing in tissue regenerative implants for patients with knee injuries. Founded in 2008 by Dr. Nick Skaer and Professor Oliver Kessler, the company leverages silk technology developed at Oxford University to create innovative solutions for cartilage and meniscus repair. Its primary products include FibroFix, a biomaterial designed to replicate human knee cartilage; FibroFix Meniscus, which focuses on repairing and regenerating meniscal cartilage; and FibroFix Cartilage, aimed at treating articular cartilage damage. The technology behind these products was originally developed at Oxford Biomaterials Ltd., where Dr. Skaer played a significant role in advancing the FibroFix technology platform before securing exclusive licenses for its application in cartilage and bone repair.
Glyconics Ltd. is a diagnostics company based in Cambridge, United Kingdom, that develops portable infrared spectroscopy devices for the diagnosis and monitoring of chronic and acute diseases, particularly respiratory conditions such as chronic obstructive pulmonary disease (COPD). Incorporated in 2013, the company has created a hand-held, miniaturized device that enables patients to collect and analyze sputum samples at home. Utilizing Fourier transform infrared spectroscopy (FTIR), the device identifies specific biomarkers associated with COPD, facilitating timely medical assessments and improved patient management.
Oxehealth Ltd. is a technology company based in Oxford, United Kingdom, specializing in non-contact vital signs monitoring solutions for various sectors, including healthcare, fitness, automotive, and security. Founded in 2012, Oxehealth has developed the Oxecam software, which utilizes a digital video camera to remotely measure vital signs such as heart rate, respiratory rate, and blood oxygenation without physical contact. This innovative technology is particularly beneficial for monitoring elderly and vulnerable individuals in settings where staff presence may be limited. Oxehealth's Digital Care Assistant generates alerts regarding risky activities and provides objective data on patient activity and vital signs, enhancing care planning and allowing caregivers to focus on hands-on support. The company has achieved a world-first certification for its software as a medical device, demonstrating its commitment to transforming care environments. Oxehealth's proprietary algorithms leverage deep learning and computer vision to deliver accurate monitoring, making it a valuable tool in mental health, prison, and acute care settings.
MICAs novel patented technology utilises magnetic nanoparticles to control cell behaviour inside and outside the body using custom designed and built magnetic arrays. Using this technology we have established a novel dynamic drug screening assay, DYNASCREEN. Further stem cell therapy applications have been explored with ambitions of clinical adoption for the treatment of bone and cartilage injuries. MICA scientists are experienced in functionalising magnetic nanoparticles with any antibody, peptide or small molecule to suit a range of applications.
Zilico Limited is a Manchester-based company focused on developing diagnostic devices aimed at improving cancer detection, particularly cervical cancer. Utilizing electrical impedance spectroscopy technology, Zilico's flagship product, ZedScan, operates alongside colposcopy to provide real-time, objective assessments of cervical epithelial tissue. This technology addresses the limitations of traditional diagnostic methods, which often involve subjective interpretations. Zilico is actively working on two applications: one targeting the referral market and another aimed at the screening market, both designed to enhance diagnostic accuracy and reduce the subjectivity associated with current practices. Since its founding in 2006, Zilico has aimed to deliver significant health economic benefits and improve cancer screening programs. The company was previously known as Aperio Diagnostics Limited before rebranding in 2008.
MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, focused on developing a novel class of anti-infective medicines derived from DNA Minor Groove Binders (MGB). Established in 2009, the company is dedicated to creating small molecule antibacterial agents effective against both multi-resistant and susceptible Gram-positive pathogens. One of its key products, MGB-BP-3, is being developed in an oral formulation for the treatment of Clostridium difficile associated disease. By targeting bacteria through a unique mode of action, MGB Biopharma aims to address the challenge of antibiotic resistance, offering healthcare providers more effective treatment options for bacterial infections. The experienced team at MGB Biopharma leverages expertise from the pharmaceutical and biotechnology sectors to drive its innovative research and development efforts.
Cydar Limited develops a fusion imaging software to the healthcare industry. It offers Cydar Medical, a fusion imaging software that delivers automated 3D overlays into the operating room for surgical guidance. The company was incorporated in 2012 and is based in Barrington, United Kingdom with additional office in Wilmington, Delaware.
New Media Education
Seed Round in 2014
New Media Education (NME) is the creator of Meducation and of various medical tutorials for UK medical students. Founded in 2008 NME aims to improve the quality of medical education worldwide. In 2009 the company launched Meducation, a social network initially aimed at UK medical students, which encourages interaction between geographically-diverse medical students. It also provides access to a large amount of free educational resources submitted by the community, as well as purchasable resources created by both NME and other small publishers. As of July 2013, Meducation had 30,000 members including 33% of UK medical students. NME is currently raising a £350k funding round to expand their services both internationally and to doctors and nurses. They expect to close the round during August 2013, hiring 6 new staff through September, and launching the first of their new products later in that year.
Lightpoint Medical, Ltd., a medical device company, develops imaging technologies for cancer surgery. It develops Cerenkov Luminescence Imaging technology that detects cancer in real-time during surgery, and reduces the likelihood of cancer recurrence and the need for reoperation. Lightpoint Medical, Ltd. was formerly known as Artemis Diagnostics Ltd. and changed its name to Lightpoint Medical, Ltd. in January 2013. The company was founded in 2012 and is based in Rickmansworth, United Kingdom.
Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, specializing in tissue regenerative implants for patients with knee injuries. Founded in 2008 by Dr. Nick Skaer and Professor Oliver Kessler, the company leverages silk technology developed at Oxford University to create innovative solutions for cartilage and meniscus repair. Its primary products include FibroFix, a biomaterial designed to replicate human knee cartilage; FibroFix Meniscus, which focuses on repairing and regenerating meniscal cartilage; and FibroFix Cartilage, aimed at treating articular cartilage damage. The technology behind these products was originally developed at Oxford Biomaterials Ltd., where Dr. Skaer played a significant role in advancing the FibroFix technology platform before securing exclusive licenses for its application in cartilage and bone repair.